iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 9 **Issue:** III **Month of publication:** March 2021

DOI: https://doi.org/10.22214/ijraset.2021.33145

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429
Volume 9 Issue III Mar 2021- Available at www.ijraset.com

Comparative Study of Drug Analysis *via* Spike Protein Binding Site Recognition and Vaccine Development of Novel Corona Virus

Pratik Chatterjee
Department of Integrative Biology, Microbial Molecular Biology Laboratory, School of BioSciences and Technology, Vellore Institute of Technology (VIT), Vellore- 632014, Tamilnadu, India

Abstract: ***The coronavirus outbreak in recent times has created a terrific pandemic situation in the universe. We aim to identify the specific domain in the viral particle responsible for binding into the host cell and for finding any anti-viral drug that could inhibit the binding interaction. Using pharmacophore-based drug modelling for drug molecule that can inhibit the spike protein interaction is targeted. Spike protein of a viral body (SARS-CoV-2) represents a structure that acts as the ligand that binds with the host, made up of several repeats of Beta sheets acts as the substrate-binding domain part. The anti-viral drug or the antibody inhibit the interaction between the spike and the receptor, are predicted via receptor-ligand interaction of the desired or predictable drug molecule. Common and trusted anti-viral strategies directed to S-protein consist of mitigation of host recognition by acting on S1-RBD (Spike Protein Receptor Binding Domain) coupled with inhibition of fusion process by acting at the level of S2 sub-unit has been explored. Drugs like Favipiravir and Barcitinib are in use to reduce viral entry in the host cells, along with several developing vaccines.***

Keywords: nCov2, S proteins, S2 subunits, ACE2 receptor, Favipiravir, Baricitinib, Vaccines.

I. INTRODUCTION

The Coronavirus illness of 2019 (COVID-19) is a respiratory tract disease, serious intense respiratory disorder Covid (SARS-CoV-1) brought about by a recently emerged Covid, nCov2, an infection considered to have a zoonotic source [1] [2]. In December of 2019, another novel Covid (SARS-CoV-2), which causes Covid illness (COVID-19), seemed to have crossed species obstructions and begun contaminating people and was viably communicated from individual to individual making the sickness infectious, prompting an episode in Wuhan, China unexpectedly. The infection slowly spread everywhere on the world, making the World Health Organization (WHO) to declare a pandemic on 11 March 2020 [3] [4]. Till date, SARS-CoV-2 keeps on representing a significant degree of worldwide wellbeing danger and financial weight. The quality sequencing investigation of the infection connotes that SARS-CoV-2 is a beta Covid which is firmly connected to SARS-CoV.

The examination and study on SARS-CoV hence gave a lot of helpful data that might be straightforwardly utilized to fight against SARS-CoV-2, however the novel Covid likewise has various attributes and guarded component in certain regards, which needs more inside investigation. [5] [6] the nCoV2 have wrapped infections containing single-abandoned positive-sense RNA strand. This single-abandoned positive RNA is utilized as a format which encodes for both underlying proteins and non-primary (NSP). There is the absolute of sixteen NSPs encoded by the viral genome, which assumes a particular part in the viral replication and record, and then again, there are an aggregate of four significant underlying proteins and five to eight frill proteins [7]. These four primary proteins of the infection comprise of the film, spike, envelope and nucleocapsid proteins, which are basically needed for the viral connection, disease and impacting individually.

Among the significant sorts of underlying proteins, the S protein is practically partitioned into two subunits. In this unique circumstance, the spike glycoprotein (S protein) present on the outside of the virus has been found to play the crucial part in binding to the host cell for initiation and progression of the infection. First, the S1 fractional unit that has the receptor-binding domain (RBD), accountable for permitting the attachment to host cells and second, the S2 fractional unit mediating fusion between the virus and host cell membranes. There are several studies that reported SARS-CoV-2 utilizes the homotrimeric spike (S) compound protein to bind with the receptor human ACE2 (human Angiotensin Converting Enzyme 2; hACE2), and this mechanism is in place for viral entry.



Figure 1: Schematic of S protein & Crystal structure of RBD (complex with receptor)

The residue numbers in each and every region denotes their positions within the S macromolecule of severe acute metabolic process syndrome-coronavirus (SARS-CoV). Crystal structures of the RBD connected with the receptor involving AN interaction with the receptor angiotensin-converting catalyst two (ACE2; green). A five-stranded anti-parallel β-sheet (β1–β4 and β7) that unites the 3 short α-helices (αA–αC) organized the core half, but a two-stranded β-sheet (β5 and β6) forms the loop. N* and C* denote the amino and carboxyl termini of the RBD, severally. The RBD amino acid (magenta) and amino alkanoic acid (yellow) residue distribution. [8] The asterisks here represent six ACE2-contacting amino acid on the RBD, and 2 disulphide bonds are shown to link C323 to C348 and C467 to C474. CP, protoplasm domain; FP, fusion peptide; hour, figure repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; Tm, trans membrane domain. RBD, settled within the S macromolecule, mediates the binding of the virus to host cells that is that the most important step for the virus to move with the host cell. [8]

A. Host & Pathogen interaction:

Until now, it is known that the S macromolecule on the surface of a pestilence particle that is gift during a pre-fusion kind. Once the viral particle is in touch with a vulnerable cells the S macromolecule undergoes priming by host cellular proteases like TMPRSS2 (serine protease) to push the membrane wrapping and effective acquisition [9] [10]. The structural analysis incontestable that the RBD of SARS-CoV-2 sure with nearly 10 times larger affinity to ACE-2 than that of SARS-CoV and in receptor unbound state, the S2 domain was additional potential. [11] Spike macromolecule being the primary contact site between viruses and cells, is subjected to tremendous biological process pressure. Any changes in spike macromolecule would have a profound impact on the infectivity and transmission of viruses [12] [13]. A considerable structural arrangement of the S macromolecule is needed to fuse the membrane of the host cell [14] [15]. CoV particles are embellished with the club-shaped trimers of the S macromolecule that is 8–23-nm long. The S macromolecule determines the host response and is the crucial target for neutralizing antibodies made by the system of the infected host [16] [17]. Sequence alignments show that the four parts of the macromolecule. Additionally to its cyclic nature have sequence and chemical science similarities to the cyclic Pep42. The moorage between Proteins to macromolecule was performed to examine the four parts of the spike that match powerfully within the GRP78 Substrate Binding Domain β (SBDβ) [18].

B. S2 spike Protein Inhibitory small Molecules from the Literature

Baricitinib is a small-molecule substance of Janus kinases or Jackinibs that is employed to treat moderate-to-severe autoimmune disorder chiefly. Whereas there is a unit differing types of disease-modifying anti-rheumatic medicine (DMARDs)-available in the market for the clinical care [19] [20]. When JAK-STAT signal gets blocked by baricitinib it produces an impairment of interferon mediated anti-viral response. This can facilitate a great impact on the evolution of SARS-CoV-2 infection [21] [22]. Favipiravir is a pyrazinecarboxamide derivative which is active against the RNA viruses. Favipiravir is transformed into the ribofuranosyltriphosphate derivative by host enzymes and thus selectively inhibits the RNA-dependent RNA polymerase of the viral particle. The RNA-dependent RNA polymerase enzymes are the anti-viral target enzymes, which are required for the transcription and replication of the viral genomes which inhibit replication of the viral particle in the next step [23].

II. METHODOLOGY

The aim of our study is to block or inhibit the entry of the virus into the host cell by repressing the replication pathway of the viral particle and thus to find a possible target molecule that can inhibit the receptor protein molecule.

A. The Sequence and NMR Structure of the SARS-CoV Fusion Protein

A novel and ideal infection by a virus require a connection between the virus and the host cell surface performed by the spike glycoprotein or S protein of CoV present on the cell surface. This receptor protein molecule has been found to be the S2 domain subunit of S protein modified into a hexametric helical bundle having the hydrophobic fusogenic peptides or fusion peptides (FPs) for insertion into the membrane. The NMR structured viral protein from severe acute respiratory syndrome-related coronavirus has been retrieved from Protein data bank [24]. The chain A of 65 amino acid sequence length spike protein s2 domain has been taken with PDB code 5XJK which has a mutation site in its amino acid chain compared to the S spike protein with UniprotKb id [accession: P59594] [25]. The PDB ENTITY SEQ 5XJK_1 and UNIPROT ALIGN P59594 have a mutagenesis or a single point mutation at 34th position where aspartic acid mutated to serine, which is denoted by a point mutation.

B. Retrieval of Ligand or Small Molecule Against s2 Spike Protein

From scientific reports, it is found that two drug molecules are the best possible small molecule that could possibly inhibit the s2 domain of the spike protein family from binding with the ACE2 receptor of the host cell and thus the entry of the viral particle to the host cell will be blocked.

Based on the research studies we have chosen two inhibitory molecules one is baricitinib, and another one is favipiravir which can be a good approach of inhibiting the gene expression of the gene coded for the amino acid expression of the s2 domain of spike protein. These two ligand molecules are retrieved from the PUBCEHM [26] database and from the database the 2D SDF file can be extracted which gives us about the protein database of the selected drug molecules [27].

C. Pharmacophore Modelling in Drug Discovery

Computer-based drug discovery is a good, fast and efficient strategy for drug discovery methodology, and organic process, like molecular arrival, [28] similarity modelling, pharmacophore modelling and mapping and sequence-based virtual screening is greatly improved. (https://www.rcsb.org/structure/5XJK). In the next step the 5XJK_1 protein is refined via the process of macromolecular refinement process and thus all the hetero atoms present in the protein structure are removed. The hetero atoms together with water cluster and if there's any substance hooked up to the receptor macromolecule, co-crystal cluster and cofactors (require for the crystallized structure of the protein) are removed. Ensuing step is followed by energy step-down exploitation, Swiss PDB VIEWER package to grant the chosen macromolecule structure a stable conformational structure in order that all the forces of the atom are balanced.

Currently designated repressing molecules and selected macromolecule receptor are uploaded in an exceedingly web-based package, ZINC Pharmer [29] (http://zincpharmer.csb.pitt.edu/pharmer.html) that provides tools for constructing and refinement of pharmacophore hypotheses. The data collected from the result of the ZINC Pharmer server are selected and filtered on the basis of Lipsinki's rule.

CLC Drug Discovery work bench [30] is a web-based virtual bench which provides the access to atomic level vision to look at the protein-ligand interaction, by permitting new ideas for improvement of the binders to be quickly examined and visualized. The question result knowledge, retrieved from the metallic element information are foreign within the drug discovery work bench to look at the macromolecule-ligand interaction between the repressing molecule and also the elite protein receptor molecule [30].

III. RESULTS

A. Mutagenesis in S2 Domain of spike Protein

The background study of the s2 domain of the spike protein shows that there are several protein structure available in the PDB database, but based on the mutagenesis study and the host cell surface and receptor binding the 5XJK_1 protein from the PDB database has been used [31].

Selected with reference sequence available in the Uniprot database with id number P59594

Several mutagenesis takes place in the amino acid sequence of the P59594, which represents the S gene. Mutagenesis takes place in 323rd position of residues C → A; which signifies no effect on human ACE2 binding *in vitro*. The Mutagenesis in the 348th position and 454th position of the residue C → A and D → A both indicate the complete loss of human ACE2 binding *in vitro* [32].

B. Protein Refinement and Pharmacophore Modelling

Our protein model suggests that the S2 subunit of the spike protein is assembled into a hexameric helical bundle showing the hydrophobic fusogenic peptides or fusion peptides (FPs) for the insertion into the membrane [33] where FPs are vital in cell to cell fusion process since isolated FPs indicated direct interactions with membrane lipids fusion. The stabilized protein structure with energy minimization is ready for pharmacophore modelling through the ZINCPHARMER web tool where the protein-ligand interaction is shown (FIGURE 3). The ZINC database gives pharmacophore modelling result based on the description of molecular features that are necessary for molecular recognition of the ligands by our selected macromolecule 5XJK.

ZINCPharmer provides tools for developing and refining pharmacophore studies directly from molecular structure. Here from the TABLE 1, compounds that match a well-defined pharmacophore serve as potential lead compounds for drug discovery where the zinc data gives the reference of the available models in zinc database with specified RMSD (Root mean square deviation) values and molecular weights.

C. *The RMSD Value Calculation*

Table 1 Depiction of comparative pharmacophore used in this study

Favipiravir & receptor - ligand interaction				
Name		Atoms	Molecular weight	rmsd
1.	ZINC90743207	40	318.39	0.55
2.	ZINC83472099	52	356.48	0.55
3.	ZINC90743225	47	358.46	0.54
Bariticinib & receptor-ligand interaction				
1.	ZINC79497887	33	319.32	0.63
2.	ZINC72034207	36	333.35	0.63
3.	ZINC94993122	35	334.33	0.62
4.	ZINC73265873	50	347.41	0.66
5.	ZINC72034180	39	369.38	0.63
6.	ZINC72034216	42	383.41	0.63
7.	ZINC72034341	47	390.44	0.62
8.	ZINC72034300	49	423.47	0.63
9.	ZINC72034324	43	429.86	0.63
10.	ZINC72094553	42	430.85	0.62
11.	ZINC72034375	55	451.52	0.63
12.	ZINC60059754	55	451.52	0.63

Root Mean Square Deviation (RMSD) is the most used for calculating the quantitative measure for the similarity between emerged atomic coordinates and mostly used to measure the quality of formation of a calculated binding pose by a computational method, such as molecular docking. The Jmol-based molecular viewer in the zincpharmer web server gives the calculated rmsd values for the modelled pharmacophore which strongly gives the evidence of the good protein- ligand interaction (Table 1). A low RMSD with respect to the true binding pose, is good; ideally less than 1.5 Angstrom, or even better, less than 1 Angstrom which in this case, represents good reproduction of the correct pose. The lowest RMSD would be acceptable. It has been observed that the small molecule found from the reported literature, favipiravir bound to the protein receptor molecule have molecular weight of 356.48 and rmsd value about 0.55 which is less than 1 angstrom represents better ligand-receptor binding. In the figure 2, the structure gives the information about the protein ligand interaction between baricitinib small molecule and the receptor protein where baricitinib plays the role of the small molecule and binds to the receptor [5XJK] and based on the feature all the pharmacophore modeled are showed as the result from the zinc database where the number of rotable bonds and the rmsd values are responsible for the stable binding of the protein-ligand complex. So, as we know the lower the rmsd value, better the binding hence favipiravir ligand gives the good binding with the receptor protein target molecule which could be better way to find the cure of the disease.

Figure 3 shows that the zincpharmer web based tool is used for the 3D view of protein-ligand interaction between ligand & protein molecule which have the rmsd value about 0.63. It shows that the zincpharmer web based tool is used for the 3D view of protein-ligand interaction where baricitinib plays the role of the small molecule which binds to the receptor [5XJK] the bond acting, the pharmacophore modeled are showed as the result from the zinc database where the number of rotable bonds and the rmsd values are taken for consideration of the stable binding of the protein-ligand complex. So, as we know the lower the rmsd value, better the binding hence favipiravir ligand gives the good binding with the receptor protein target molecule.



Figure2 ZINC60059754-Baricitinib and 5xjk pharmacophore

Figure 3 ZINCPHARMER web based tool showing interaction between ligand and protein

D. Structure Visualization of the Pharmacophore

The pharmacophore molecule thus prepared could be visualized through Ligplot plus viewer where we can easily visualize the ligand molecule bound with the receptor protein molecule and thus the binding efficacy could be determined by predicting the binding pocket.

Ligplot plus shows the intermolecular bonds between the atoms of the receptor molecule and the drug molecule which is a graphical tool for automatically evolving multiple 2D diagrams of ligand-protein interactions from three dimensional coordinates. The system in the ligplot plus is able to plot, in the same orientation, related sets of ligand-protein interactions. This facilitates popular research tasks, such as analyzing a series of small molecules binding to the same protein target, a single ligand binding to homologous proteins.

IV. ADVANCEMENT IN VACCINE DEVELOPMENT

Developing human-use vaccines would take many years and presumably many million financial assistance, particularly new technologies that haven't have not been thoroughly examined for safety or expanded to mass producing .Since there are no efficacious coronavirus vaccines on the market, and there has been no large-scale process capability for such vaccines hitherto (Table 2), such processes and technologies would wish to be developed.They might be complicated, exacting, and long for the primary time. In an mRNA-based immunization, in which mRNAs are typified in lipid nanoparticles, communicates an objective antigen in vivo. It was co-created by Moderna and the National Institutes of Health Vaccine Development Center, which has as of late dispatched a stage III clinical preliminary (ClinicalTrials.gov: NCT04470427) 29. Curevac has been building up a comparable immunization, which is as yet in a pre-clinical stage.

Numerous immunizations, for example, recombinant protein-based subunit antibodies, viral-vector antibodies, DNA antibodies, live attenuated immunizations, and inactivated infection immunizations, are currently in the pre-clinical stage (Fig. 4; Table 2). Since these systems have the two advantages and disadvantages, it is hard to characterize which approach would be speedier or more powerful (Table 2).

Little is perceived about SARS-CoV-2 etiology, the study of disease transmission, useful root, pathogenic cycle, neurotic resistant reactions, etc. Moreover, the host cell and humoral insusceptible reactions to SARS-CoV-2, which are significant for the improvement of antibodies, stay obscure. These issues are to be handled in the short term through essential investigations for immunizations' successful turn of events. Numerous nations and R&D organizations have proclaimed their arrangements for SARS-CoV-2 immunization improvement. The planning of immunization competitors as such is anything but an imposing errand, on the grounds that

the system for delivering antibody contender for SARS-CoV-2 is basically equivalent to that for SARS-CoV. Unexpectedly, it is very hard to inspect numerous issues, including wellbeing, defensive impacts, and a predictable antibody organization level. When all is said in done, the security, immunogenicity, and viability of the immunization will be tried across three periods of clinical preliminaries. Normally, it requires over 10 years to dispatch new antibodies, and over 90% of the competitors neglect to be documented by the administrative power. In the course of the most recent thirty years, a record of around 3,000 immunization definitions have been There were 149 transformation destinations in 103 sequenced SARS-CoV-2 genomes, and the infection has formed into two unique variations, called L and S, in the beginning phase of COVID-19 in Wuhan. The exploration additionally uncovered that the two variations showed critical local spread and scattering varieties, prompting antibody configuration challenges. Clinical preliminaries assessing various medicines are in progress, ideally prompting finding another prescription to battle SARS-CoV-2-related infections applied to the audit of the U.S. Food and Drug Administration (USFDA), and under 20 antibodies have been approved available to be purchased. For public security, we need to create antibodies in consistence with science enactment for advancement and producing, and tough laws administering its selling.

Initially, the pandemic keeps on growing around the world, and an ever increasing number of announced cases are being found, and the expression point has not been accomplished. Besides, diseases with SARS-CoV-2 will turn into an influenza like occasional sickness, and long exist together with people. It should be recollected that SARS-CoV-2 has been accounted for over a year, and SARS-CoV-2 is still uncertain.

Table 2 A summary of SARS-CoV-2 vaccine development platforms

Platforms	Benefits	Drawbacks
Inactivated vaccines	An easy procedure employed by several approved human vaccines, current facilities could also be used, SARS-CoV adjuvants are evaluated in humans and will be wont to improve immunogenicity.	Vast quantities of the contagious virus should be treated. The integrity of the antigens and/or epitopes should be verified.
Live attenuated vaccines	Existing technology will be used with straightforward procedures needed by several approved medical vaccines.	Because of its full order size, it needs time to make infectious clones for attenuated coronavirus vaccinum seeds. There would need to be thorough observance of safety.
Viral vector-based vaccines	There is no ought to diagnose a contagious virus, outstanding presymptomatic, and clinical proof for different new infections, like MERS-CoV.	Vector immunity might have a prejudicious impact on the efficaciousness of the immunizing agent (based totally on vector selected).
Subunit (recombinant protein) vaccines	There is no ought to treat associate infectious virus; adjuvants could also be utilised to boost immunogenicity.	The capability to provide recombinant proteins for world use may be restricted. The integrity of the antigens and/or epitopes should be tested. Yields ought to be high enough.
DNA vaccines	There is no need to manage the contagious virus, quick scaling up, low price of process, high heat stable, SARS-CoV testing in humans, fast development possible.	To achieve robust immunogenicity, the immunogen needs totally different distribution systems
RNA vaccines	There is no ought to treat a contagious virus; vaccinations square measure typically immunogenic and certain quick development.	Reactogenicity-related safety considerations were known.

Table3 Mot common drugs and clinical outcomes

Drugs	Classification	Mechanism of action	Outcome- clinical trial	Recommendation against COVID-19
Remdesivir [35]	Investigational nucleoside analogue	Inhibits the viral RNA synthesis-(RdRps)	Better clinical improvement	NIH and FDA recommendation
Favipiravir [36]	Investigational RNA-dependent RNA polymerase inhibitor	Inhibits the viral RNA synthesis	Shortening the recovery time,better efficacy	Approved in China
Chloroquine and hydroxichloroquine [37]	Antimalarial drug	Inhibits viral enzymes or processes, ACE2 cellular receptors acidifies the cell membrane surfaces	Active against SARS-CoV-2 inhibits the exacerbation of pneumonia	Used for whom clinical trial participation is not feasible
Ivermectin [38]	Anti-parasite	Inhibits the coupling of the SARS-CoV-2S-protein with the human ACE2 receptor	Induces approximately 5000-fold reduction in the viral RNA of SARS-CoV-2 at 48 h	NA
Baricitinib and ruxolitinib [39]	Janus kinases inhibitor	Inhibits Janus kinases enzymes and alleviate the signal transmission due to cytokine storm	Improved clinical symptoms and respiratory parameters of baricitinib patients compared to control,	NIH recommends against the use of these drugs outside of clinical trials
Nitazoxanide [40]	Antiviral	preventing viral entry	No clear safety data	NA



Figure 4 Summary of SARS-CoV-2 vaccine development in future ((S) protein of SARS-CoV-2)

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429
Volume 9 Issue III Mar 2021- Available at www.ijraset.com



Figure 5 Mechanisms of action of various therapeutic agents being deployed against SARS-CoV-2 and COVID-19

V. DISCUSSION

ZINC Pharmer takes care of the generation and storage of an outsized multi-conformer information of the biologically relevant and commercially accessible compounds of the Zn information. Our study may embody a new method for locating a new drug, therefore making a new lead for the drug development pathway that signifies the exactitude drug within close to future. There is no any specific medicine available for the anti-viral treatment of SAR CoV.Some approved medicines are penciclovir, nitazoxanide, nafamostat, antimalarial (CQ) and 2 well-known broad-spectrum anti-viral medicine remdesivir (RDV, GS-5734) and favipiravir (T-705) and were evaluated against a clinical isolate of 2019-nCoV in vitro. Baricitinib can be used to reduce the ability of the virus to infect the host cells. It inhibits the Janus kinase pathway which binds the cyclin G associated kinase, the regulator of receptor cell endocytosis. RDV, has shown a diverse activity against SAR CoV , MerS – CoV, Ebola Virus. It is an adenosine pro-drug, which results in premature termination of RNA synthesis. [34] Thus developed pharmacophore model from our study could indicate a way in drug development which can inhibit the binding of the ACE2 receptor with the s2 fusion protein of ncov2. Favipiravir is a pyrazine carboxamide derivative (6 - fluro -3- hydroxy-2- pyrazine carboxamide) which is phophorylated and ribosylated intracellularly to form activated metabolite favipivarir ibofuranosyl -5'- triospjophosphate (T-705-RTP). Active Favipiravir RTP form inhibits RdRp Replication of RNA virus thereby blocking viral replication and inhibiting synthesis of viral proteins within in the cell. Moderma , a lead developer is in the the Phase I trial of vaccine candidate mRNA -1273, a novel lipid nanoparticle (LNP) - encapsualted mRNA basedvaccine that encodes for a full - length, prefusion stabilised spike

In the Table 3, the data gives us the information on the summary of the mechanism of action, the current ongoing output of few clinical therapeutic trials, and FDA recommendation to use against COVID-19 for the betterment of the world health. A recent study with patients affected with COVID-19 have depicted that the induction of ivermectin results into the reduction of viral RNA of SARS-CoV-2, though it has been reported that the antiviral concentration of ivermectin was achieved only after a large dose. Nitazoxanide being an antiprotozoal drug, shows its antiviral activity by interacting with the viral genome synthesis, thus preventing viral entry into the host cell, and interfering with the N-glycosylation. But as it has no meticulous safety data for patients with renal or hepatic impairment, based on the available data, the antiviral activity of nitazoxanide for SARS-CoV-2 requires more study and research work.

A. *Predominance of Comorbidities Among People with COVID-19*

The clinical indications of determined people to have COVID-19 can be transcendently described through a bunch of influenza like manifestations (fever, hack, dyspnea, myalgia, exhaustion, looseness of the bowels, and smell/taste problem); anyway asymptomatic cases have additionally been confirmed. Major perilous intricacies of the infection much of the time incorporate intense respiratory misery disorder, intense renal injury, intense coronary injury, and at least one organ disappointment or dysfunction [41]. These serious confusions appear to be deteriorated in COVID-19 patients who are old (>60) or potentially with at least one comorbidities. [42] [43] Initial information on clinical attributes from Wuhan, China recommended that 32% of COVID-19 positive patients had hidden sicknesses comprising of cardiovascular illness (CVD), hypertension (HTN), diabetes, and constant obstructive pneumonic sickness (COPD).Soon after, a Nationwide measurement from China on the clinical qualities and results of COVID-19 patients likewise uncovered that among the analyzed cases most had at least one coinciding conditions. Subsequently, fundamental information from the United States, EU/EEA likewise affirmed that people with significant comorbidities including CVD, HTN, diabetes, COPD, CKD, and threat appear to be at higher danger than those without these conditions for extreme COVID-19 complications [44]. Requirement for hospitalization and emergency unit confirmations with COVID-19 have been seen in about 20% of cases with polymorbidity, with case casualty rates as high as 14%. Overall, composite information proposes that people with ongoing basic ailment may have extreme result hazards as high as 10-overlay when contrasted with people with no comorbidity. Along these lines, given the gigantic wellbeing and monetary weight of COVID-19, exhaustive assessment of the affiliation and pervasiveness of comorbidities in COVID-19 patients is required in fighting this worldwide pandemic. The point of our audit is to investigate the predominance of top worldwide comorbidities (CVD, Diabetes, COPD, Cancer, and CKD) among people with COVID-19, just as explore any critical associations.[45] Studies distinguishes weak patient populaces who are at expanded danger of extreme COVID-19 entanglements while educating clinicians, strategy creators, and analysts as new procedures and strategies are created to moderate the impacts of the COVID-19 pandemic.

VI. CONCLUSION

In this study, the aim was to find out a possible anti-viral drug, which might inhibit the infection through the inhibition of the interaction between the S-protein and the ACE2 receptor on cells in respiratory organ. The association between the S macromolecule of SARS-CoV and ACE2 is needed for the entry of SARS-CoV. The general growth of the epidemic SARS-CoV strains most possibly occurred since a long time period, through the repetitive transmission of viruses from animals to humans and from humans to animals, thus creating mutations in both the SARS-CoV S protein and ACE2, so that human and animal SARS-CoVs could get an entry into the cells that bore human or animal ACE2. Another study gives us the idea of the tropism of the virus and the mechanism of the SARS-CoV S protein in receptor binding and hence entry is important for developing the anti-SARS-CoV therapeutics and vaccines.

The comprehensive study refers that the viability of small protein molecules and small molecules such as ligands to be used as anti-SARS therapeutics is partly limited by their lower antiviral potential. In addition, the probability of inducing the viral entry might block monoclonal antibodies as immunotherapeutic for long-term use. It can be assumed that S protein-based vaccines will bear fruit in the very near future, since they have been proven to induce long-term and can be potential in neutralizing antibodies or can show protective immunity against SARS-CoV. However the in vivo efficiency of these vaccine candidate drugs in matured and lethal-challenged models, and their protection towards the zoonotic virus infection, should be examined before a clinical study is initiated. Considering all these factor into a depth, an amalgamation of different approaches with numerous vaccines and antiviral therapeutics may be required to initiate broad and cross protection against different types of virus strains, especially which have been isolated get mutated quickly [46]. Based on the analysis study yet, it has a tendency to find the invention of the potential drug and precision medicine within close to future to provide a permanent finish to the current pandemic.

REFERENCES

[1] Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. 10.1056/NEJMoa030747
[2] Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. SARS Working Group A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953-66. 10.1056/NEJMoa030781
[3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-207. 10.1056/NEJMoa2001316
[4] Coronavirus disease (COVID-19) outbreak Geneva: World Health Organization; 2020. [Accessed 3 May 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

[5] Zhou P, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.
[6] Li W, Farzan M, Harrison SC. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
[7] Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi: 10.1002/jmv.25681.
[8] Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16; 309(5742):1864-8.
[9] Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301.
[10] Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 doi: 10.1016/j.cell.2020.02.052.
[11] Wang X., Xu W., Hu G., Xia S., Sun Z., Liu Z., Xie Y., Zhang R., Jiang S., Lu L. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cellular & Molecular Immunology. 2020:1–3. doi: 10.1038/s41423-020-0424-9.
[12] Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.
[13] Xia S., Liu M., Wang C., Xu W., Lan Q., Feng S., Qi F., Bao L.,. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–355. doi: 10.1038/s41422-020-0305-x. J Infect. 2020 May; 80(5): 554–562.
[14] Bosch B.J., van der Zee R., de Haan C.A.M., Rottier P.J.M. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 2003;77:8801–8811. doi: 10.1128/jvi.77.16.8801-8811.2003.
[15] Hulswit R.J.G., de Haan C.A.M., Bosch B.-J. Chapter Two - coronavirus spike protein and tropism changes. In: Ziebuhr J., editor. Advances in Virus Research, Coronaviruses. Academic Press; 2016. pp. 29–57.
[16] Hofmann H., Hattermann K., Marzi A., Gramberg T., Geier M., Krumbiegel M., Kuate S., Uberla K., Niedrig M., Pöhlmann S. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 2004;78:6134–6142. doi: 10.1128/JVI.78.12.6134-6142.2004.
[17] Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and Antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292. doi: 10.1016/j.cell.2020.02.058. e6.
[18] Ibrahim M. Ibrahim,a Doaa H. Abdelmalek,a Mohammed E. Elshahat,a and Abdo A. Elfiky. COVID-19 spike-host cell receptor GRP78 binding site prediction. Published online 2020 Mar 10. doi: 10.1016/j.jinf.2020.02.026 PMCID: PMC7102553 PMID:32169481.
[19] Smolen JS Genovese MC Takeuchi T et al.Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019; 46: 7-18.
[20] Biggioggero M Becciolini A Crotti C Agape E Favalli EG Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019; 8212595.
[21] Stebbing J, Phelan A, Griffin I, et al..Fleming SB Viral inhibition of the IFN-induced JAK/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines (Basel). 2016; 4.
[22] Sergio Lo Caputo, 1 Gaetano Corso, 2 Mario Clerici, 3 and Teresa Antonia ,Baricitinib: A chance to treat COVID-19 .
[23] Favipiravir: A new and emerging antiviral option in COVID-19 Umang Agrawal,a Reyma Raju,b and Zarir F. Udwadiac,∗ doi: 10.1016/j.mjafi.2020.08.004 PMCID: PMC7467067 PMID: 32895599.
[24] Mahajan, M., Chatterjee, D., Bhuvaneswari, K., Pillay, S., Bhattacharjya, S.(2017) NMR structure and localization of a large fragment of the SARS-CoV fusion protein: Implications in viral cell fusion. PubMed: 28988778
[25] Wu CH, Nikolskaya A, Huang H, Yeh LS, Natale DA, Vinayaka CR, Hu ZZ, Mazumder R, Kumar S, et al. PIRSF: family classification system at the Protein Information Resource. Nucleic Acids Res. 2004;32:D112–D114.
[26] Sunghwan Kim, Paul A. Thiessen, Evan E. Bolton, Substance and Compound databases Published online 2015 Sep 22. doi: 10.1093/nar/gkv951 PMCID: PMC4702940 PMID: 26400175.
[27] Bolton E.E., Wang Y., Thiessen P.A., Bryant S.H. PubChem: integrated platform of small molecules and biological activities. In: Wheeler RA, Spellmeyer DC, editors. Annual Reports in Computational Chemistry. Vol. 4. Amsterdam: Elsevier; 2008. pp. 217–241.
[28] Myers S, Baker A. Drug discovery - an operating model for a new era. Nat Biotechnol 2001; 19: 727–3 Shekhar C . In silico pharmacology: computer-aided methods could transform drug development. Chem Biol 2008; 15: 413–4.
[29] Nucleic Acids Res. 2012 Jul; 40(Web Server issue): David Ryan Koes* and Carlos J. Camacho ZINCPharmer: pharmacophore search of the ZINC database W409–W414. Published online 2012 May 2. doi: 10.1093/nar/gks378 PMCID: PMC3394271 PMID: 22553363.
[30] Bendtsen, J. D., Jensen, L. J., Blom, N., Heijne, G. V., and Brunak, S. (2004a). Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel, 17(4):349-356.
[31] Wong S.K., Li W., Moore M.J., Choe H., Farzan M. J. Biol. Chem. 279:3197-3201(2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
[32] Wong S.K., Li W., Moore M.J., Choe H., Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
[33] Mukesh Mahajan, Deepak Chatterjee, Kannaian Bhuvaneswari, Shubhadra Pillay, and Surajit Bhattacharjya, NMR structure and localization of a large fragment of the SARS-CoV fusion protein: Implications in viral cell fusion doi:10.1016/j.bbamem.2017.10.002 PMID: 28988778.
[34] Cynthia Liu, Cynthia Liu,Qiongqiong Zhou, Yingzhu Li, Daniels, Susan Jervey, and Dana Albaiu.] Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent. Sci. 2020, 6, 3, 315–331.
[35] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.
[36] Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512.

[37] Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5(1_suppl):4–10.
[38] Sajid MS, Immunomodulatory effect of various anti-parasitics: a review. Parasitology. 2005;132(3):301–13.
[39] Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318–56.
[40] Rossignol J-F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antivir Res. 2014;110:94–103.
[41] McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features
[42] Wang X, Fang X, Cai Z. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: a aystemic review and meta-analysis. Research. 2020;2020:1.
[43] Hu Y, Sun J, Dai Z. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol. 2020;127.
[44] Coronavirus disease 2019 (COVID-19) in the EU/EEA. European Center for Disease Prevention and Control.
[45] Noncommunicable diseases 2020. The Global Health Observatory.
[46] Ashleigh Shannon, Barbara Selisko, Nhung-Thi-Tuyet Le, Johanna Huchting, Franck Touret, Géraldine Piorkowski, Véronique Fattorini, François Ferron, Etienne Decroly, Chris Meier, Bruno Coutard, Olve Peersen. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis Nature Communications volume 11, Article number: 4682 (2020)



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY